Skip to main content
Strategic Partners A/S logo

Strategic Partners A/S — Investor Relations & Filings

Ticker · STRAP ISIN · DK0062502894 LEI · 54930025OZD2GGSQ7L42 CO Financial and insurance activities
Open in API
Filings indexed 501 across all filing types
Latest filing 2019-07-15 Board/Management Inform…
Country DK Denmark
Listing CO STRAP

About Strategic Partners A/S

https://www.strategic-partners.dk/

Strategic Partners A/S is an investment company that engages in strategic partnerships with businesses that have significant potential. The company's strategy involves taking an active ownership role to create value through its competencies. In addition to its primary focus, the firm may also invest in other equity interests and properties to generate returns. Formerly known as Orphazyme A/S, the company sold its biotechnology activities in May 2022. A new board and management team was appointed in May 2023, and the company officially adopted its new strategy, purpose, and name in October 2024.

Recent filings

Filing Released Lang Actions
Board/Management Information 2019
Board/Management Information Classification · 100% confidence The document is a press release announcing a significant change in senior management: the appointment of Kim Stratton as the new Chief Executive Officer, succeeding the co-founder. This directly aligns with the definition of 'Board/Management Information' (MANG). The text is a formal announcement, not a comprehensive financial report (like 10-K or IR) or a short announcement of a report (RPA/RNS). The document length (8552 chars) is substantial enough to be the primary content itself, not just a cover note.
2019-07-15 English
Orphazyme to prepare for filing of arimoclomol in Europe for Niemann-Pick disease Type C (NPC)
Regulatory Filings Classification · 95% confidence The document is a company announcement from Orphazyme A/S regarding regulatory progress for a drug candidate. It is a short press release (under 5,000 characters of core content) that provides an update on interactions with the EMA and future filing plans. Crucially, it includes an 'Attachment' section with a link to the full document, which triggers the 'Menu vs Meal' rule, classifying it as a Report Publication Announcement (RPA).
2019-06-07 English
Legal Proceedings Report 2019
Legal Proceedings Report Classification · 99% confidence The document is a formal announcement from Orphazyme A/S, dated June 7, 2019, detailing regulatory progress regarding their drug arimoclomol for Niemann-Pick disease Type C (NPC). It discusses receiving advice from the EMA and the intention to file a Marketing Authorization Application (MAA) in H1 2020. This is a specific corporate update regarding regulatory pathways and future filings, not a full financial report (10-K, IR), an earnings release (ER), or a transcript (CT). It is an announcement about regulatory/development progress. Since there is no specific category for 'Regulatory Pathway Update' or 'Clinical Development News', and it is not a general regulatory filing (RNS) or a management change (MANG), it best fits under 'Regulatory Filings' (RNS) as a general announcement of corporate activity that doesn't fit the other specific categories, or potentially 'LTR' if the EMA interaction is viewed as a regulatory matter, but RNS is the broader fallback for non-financial, non-management announcements. Given the context of providing updates on drug development and regulatory steps, RNS (Regulatory Filings/General Announcement) is the most appropriate general classification for this type of press release when a more specific regulatory/clinical category is absent.
2019-06-07 English
Major shareholder announcement
Major Shareholding Notification Classification · 100% confidence The document is a formal notification from Orphazyme A/S regarding a change in shareholding by Danske Bank A/S, specifically citing Section 38 of the Danish Capital Markets Act. This is a standard disclosure for when a shareholder crosses a specific ownership threshold, which falls under the 'Major Shareholding Notification' category.
2019-05-31 English
Major Shareholding Notification 2019
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'Major shareholder announcement' and details a notification received pursuant to Section 38 of the Danish Capital Markets Act regarding a change in shareholding percentage (4.99% ownership, 7.74% voting rights) by Danske Bank A/S. This directly corresponds to the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2019-05-31 English
Orphazyme’s Phase II/III trial in sporadic Inclusion Body Myositis fully enrolled
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the status of a clinical trial (enrollment completion). It does not fit into specific financial reporting categories like 10-K, IR, or ER. As it is a general corporate announcement regarding operational progress (clinical trials) that does not fall into the other specialized categories, it is best classified as a Regulatory Filing (RNS).
2019-04-23 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.